Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 2, 2026, 2:32 PM EST

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 697–720 of 9,120 matching trials from the live ClinicalTrials.gov search.
Filters: Tampa, Florida Clear all
Terminated Phase 2 Interventional Results available

An Extension Study of ABBV-8E12 in Progressive Supranuclear Palsy (PSP)

NCT03391765
View directory record Official record
Conditions
Progressive Supranuclear Palsy (PSP)
Interventions
ABBV-8E12, Placebo solution for IV infusion on Day 15
Drug
Lead sponsor
AbbVie
Industry
Eligibility
40 Years and older
Enrollment
142 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
24
States / cities
Birmingham, Alabama • Phoenix, Arizona • Beverly Hills, California + 19 more
Source: ClinicalTrials.gov public record
Updated Feb 3, 2021 · Synced Nov 2, 2026, 2:32 PM EST
Completed Phase 2 Interventional Results available

Nilotinib in Patients With Relapsed or Metastatic Pigmented Villonodular Synovitis/Tenosynovial Giant Cell Tumor/Diffuse-Type Giant Cell Tumor

NCT01207492
View directory record Official record
Conditions
Pigmented Villonodular Synovitis, Diffuse-type Giant Cell Tumor, Tenosynovial Giant Cell Tumor
Interventions
nilotinib
Drug
Lead sponsor
Andrew J. Wagner, MD, PhD
Other
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
7
States / cities
Santa Monica, California • Stanford, California • Tampa, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Feb 20, 2026 · Synced Nov 2, 2026, 2:32 PM EST
Completed Phase 3 Interventional Results available

Efficacy and Safety of Targeted Intramyocardial Delivery of Auto CD34+ Stem Cells for Improving Exercise Capacity in Subjects With Refractory Angina

NCT01508910
View directory record Official record
Conditions
Chronic Myocardial Ischemia, Refractory Angina Pectoris, Advanced Coronary Heart Disease
Interventions
Auto-CD34+ cells, Placebo: Diluent used to suspend Auto-CD34+ cells, Standard of care
Biological · Other
Lead sponsor
Lisata Therapeutics, Inc.
Industry
Eligibility
21 Years to 80 Years
Enrollment
291 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
41
States / cities
Birmingham, Alabama • Gilbert, Arizona • Phoenix, Arizona + 38 more
Source: ClinicalTrials.gov public record
Updated Dec 19, 2018 · Synced Nov 2, 2026, 2:32 PM EST
Completed Phase 2 Interventional

A Phase II, Randomized Study of ACZONE™ (Dapsone) Gel, 5% for Papulopustular Rosacea.

NCT00249782
View directory record Official record
Conditions
Rosacea
Interventions
Vehicle control, 2x/day, ACZONE (dapsone) Gel, 5%, 2x/day, ACZONE (dapsone) Gel, 5%, 1x/day, MetroGel® (metronidazole gel), 1.0% 1x/day, ACZONE (dapsone) Gel, 5%, 1x/day (AM) + MetroGel (metronidazole gel), 1.0%, 1x/day (PM)
Drug
Lead sponsor
Allergan
Industry
Eligibility
18 Years and older
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
26
States / cities
Birmingham, Alabama • Tucson, Arizona • Fremont, California + 21 more
Source: ClinicalTrials.gov public record
Updated May 30, 2011 · Synced Nov 2, 2026, 2:32 PM EST
Completed Phase 2 Interventional Results available

Study of Durvalumab Following Radiation Therapy in Patients With Stage 3 Unresectable NSCLC Ineligible for Chemotherapy

NCT04249362
View directory record Official record
Conditions
Non-small Cell Lung Cancer
Interventions
Durvalumab
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
102 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
3
States / cities
Tucson, Arizona • Tampa, Florida • Royal Oak, Michigan
Source: ClinicalTrials.gov public record
Updated Jan 10, 2025 · Synced Nov 2, 2026, 2:32 PM EST
Completed Phase 2 Interventional Results available

Comparator Study of the Effect of Glycopyrrolate and Glycopyrronium in Subjects With Axillary Hyperhidrosis

NCT02129660
View directory record Official record
Conditions
Hyperhidrosis
Interventions
Dose 1 of glycopyrrolate, 2.0% QD, Dose 2 of glycopyrrolate, 3.0% QD, Dose 1 of glycopyrronium, 2.5% QD, Dose 2 of glycopyrronium, 3.75% QD, Vehicle
Drug · Other
Lead sponsor
Journey Medical Corporation
Industry
Eligibility
18 Years to 99 Years
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
14
States / cities
Encinitas, California • Fremont, California • Tampa, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Sep 17, 2025 · Synced Nov 2, 2026, 2:32 PM EST
Completed Phase 3 Interventional Results available

A Study of S6G5T3 in the Treatment of Acne Vulgaris

NCT03761810
View directory record Official record
Conditions
Acne Vulgaris
Interventions
S6G5T-3, S6G5T-8
Drug
Lead sponsor
Sol-Gel Technologies, Ltd.
Industry
Eligibility
9 Years and older
Enrollment
434 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Dec 16, 2021 · Synced Nov 2, 2026, 2:32 PM EST
Completed Not applicable Interventional Results available

InterStim Basic Evaluation Lead Post-Market Clinical Follow-up Study

NCT04016324
View directory record Official record
Conditions
Overactive Bladder, Urinary Urge Incontinence, Urgency-frequency Syndrome
Interventions
InterStim Basic Evaluation lead and foramen needle
Device
Lead sponsor
MedtronicNeuro
Industry
Eligibility
18 Years and older
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
10
States / cities
St. Petersburg, Florida • Tampa, Florida • Plymouth, Minnesota + 7 more
Source: ClinicalTrials.gov public record
Updated Nov 23, 2021 · Synced Nov 2, 2026, 2:32 PM EST
Recruiting Phase 2 Interventional

APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors

NCT03175224
View directory record Official record
Conditions
Solid Tumors, Advanced Cancer, Renal Cancer, Gastric Cancer, Gastroesophageal Junction Adenocarcinoma, NSCLC, Lung Cancer, Brain Tumor, Glioblastoma Multiforme, EGFR Gene Mutation, MET Amplification, HGF, Thyroid Cancer, Pancreatic Cancer, Colon Cancer, MET Alteration, MET Fusion, Exon 14 Skipping
Interventions
APL-101 Oral Capsules
Drug
Lead sponsor
Apollomics Inc.
Industry
Eligibility
18 Years and older
Enrollment
497 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2026
U.S. locations
6
States / cities
Los Angeles, California • Tampa, Florida • Boston, Massachusetts + 3 more
Source: ClinicalTrials.gov public record
Updated Jun 27, 2025 · Synced Nov 2, 2026, 2:32 PM EST
Recruiting Phase 1 Interventional

Evaluation of RAS Inhibitor Treatment in Participants With Advanced or Metastatic Solid Tumors Harboring RAS Mutations

NCT07252479
View directory record Official record
Conditions
Solid Tumors (Phase 1), RAS Mutation
Interventions
AN9025 oral capsule
Drug
Lead sponsor
Adlai Nortye Biopharma Co., Ltd.
Industry
Eligibility
18 Years and older
Enrollment
118 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
3
States / cities
Orlando, Florida • Tampa, Florida • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 8, 2026 · Synced Nov 2, 2026, 2:32 PM EST
Completed Phase 2 Interventional Results available

A Clinical Study in Subjects With Neuropathic Pain From PHN Who Have Had an Inadequate Response to Gabapentin Treatment

NCT00617461
View directory record Official record
Conditions
Neuralgia, Postherpetic
Interventions
GEn 1200mg/day, GEn 3600mg/day
Drug
Lead sponsor
XenoPort, Inc.
Industry
Eligibility
18 Years and older
Enrollment
96 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
42
States / cities
Phoenix, Arizona • Oxnard, California • Roseville, California + 36 more
Source: ClinicalTrials.gov public record
Updated Jul 22, 2013 · Synced Nov 2, 2026, 2:32 PM EST
Terminated Phase 2 Interventional Results available

A Phase 2A Study to Evaluate the Safety and Effect on Exercise Challenge Testing of MEDI-528 in Adults With Asthma

NCT00590720
View directory record Official record
Conditions
Asthma
Interventions
MEDI528 50 mg, PLACEBO
Biological · Other
Lead sponsor
MedImmune LLC
Industry
Eligibility
18 Years to 50 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
9
States / cities
San Diego, California • Denver, Colorado • Waterbury, Connecticut + 6 more
Source: ClinicalTrials.gov public record
Updated Mar 21, 2014 · Synced Nov 2, 2026, 2:32 PM EST
Completed Phase 2 Interventional Results available

A Trial of Degarelix in Men With Lower Urinary Tract Symptoms (LUTS) Associated With Benign Prostatic Hyperplasia (BPH)

NCT00947882
View directory record Official record
Conditions
Lower Urinary Tract Symptoms (LUTS)
Interventions
Placebo, Degarelix 10 mg, Degarelix 20 mg, Degarelix 30 mg
Drug
Lead sponsor
Ferring Pharmaceuticals
Industry
Eligibility
50 Years and older · Male only
Enrollment
404 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
15
States / cities
Homewood, Alabama • Mobile, Alabama • Newport Beach, California + 12 more
Source: ClinicalTrials.gov public record
Updated Jun 8, 2015 · Synced Nov 2, 2026, 2:32 PM EST
Recruiting Phase 3 Interventional

Anticoagulation in ICH Survivors for Stroke Prevention and Recovery

NCT03907046
View directory record Official record
Conditions
Intracerebral Hemorrhage, Atrial Fibrillation
Interventions
Apixaban, Aspirin
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years and older
Enrollment
700 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
186
States / cities
Birmingham, Alabama • Mobile, Alabama • Chandler, Arizona + 141 more
Source: ClinicalTrials.gov public record
Updated May 8, 2026 · Synced Nov 2, 2026, 2:32 PM EST
Completed Phase 2 Interventional

Safety and Efficacy of Tegoprubart in Patients Undergoing Kidney Transplantation

NCT05983770
View directory record Official record
Conditions
Kidney Transplant Rejection
Interventions
AT-1501, Tacrolimus
Drug
Lead sponsor
Eledon Pharmaceuticals
Industry
Eligibility
18 Years to 100 Years
Enrollment
127 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
27
States / cities
Los Angeles, California • Orange, California • Sacramento, California + 23 more
Source: ClinicalTrials.gov public record
Updated Jul 22, 2026 · Synced Nov 2, 2026, 2:32 PM EST
Completed Phase 2 Interventional

A Study of RO4905417 in Patients With Non ST-Elevation Myocardial Infarction (Non-STEMI) Undergoing Percutaneous Coronary Intervention

NCT01327183
View directory record Official record
Conditions
Myocardial Infarction
Interventions
Percutaneous Coronary Intervention (PCI), RO4905417, placebo
Procedure · Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
19 Years to 74 Years
Enrollment
532 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
35
States / cities
Huntsville, Alabama • Tucson, Arizona • Los Angeles, California + 31 more
Source: ClinicalTrials.gov public record
Updated Nov 2, 2016 · Synced Nov 2, 2026, 2:32 PM EST
Completed Not applicable Interventional Accepts healthy volunteers

Glucose and Motivation States

NCT07255183
View directory record Official record
Conditions
Motivation
Interventions
Exercise, Sugar Drink, Non-sugar beverage
Behavioral · Dietary Supplement
Lead sponsor
University of South Florida
Other
Eligibility
18 Years to 45 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Aug 27, 2026 · Synced Nov 2, 2026, 2:32 PM EST
Completed Phase 2 Interventional Results available

Phase 2 Randomized, Double-Blind, Placebo-Controlled, Parallel Group Trial of Linaclotide Administered to Patients With Opioid-Induced Constipation Receiving Chronic Opioid Treatment for Non-Cancer Pain

NCT02270983
View directory record Official record
Conditions
Opioid-Induced Constipation
Interventions
Linaclotide 145 micrograms, Linaclotide 290 micrograms, Placebo
Drug
Lead sponsor
Forest Laboratories
Industry
Eligibility
18 Years and older
Enrollment
254 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
77
States / cities
Anniston, Alabama • Foley, Alabama • Phoenix, Arizona + 67 more
Source: ClinicalTrials.gov public record
Updated Apr 8, 2019 · Synced Nov 2, 2026, 2:32 PM EST
Terminated Phase 2 Interventional Results available

Randomized, Double-blind Study of Efficacy and Safety of Bexotegrast (PLN-74809) for Idiopathic Pulmonary Fibrosis

NCT06097260
View directory record Official record
Conditions
Idiopathic Pulmonary Fibrosis
Interventions
PLN-74809, Placebo
Drug
Lead sponsor
Pliant Therapeutics, Inc.
Industry
Eligibility
40 Years and older
Enrollment
320 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
79
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 69 more
Source: ClinicalTrials.gov public record
Updated Aug 5, 2026 · Synced Nov 2, 2026, 2:32 PM EST
Completed Phase 2 Interventional

Safety of NXY-059 for the Treatment of Patients Who Have Suffered From a Stroke

NCT00075959
View directory record Official record
Conditions
Intracerebral Hemorrhage
Interventions
NXY-059
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
64
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Fort Smith, Arkansas + 61 more
Source: ClinicalTrials.gov public record
Updated Jan 4, 2013 · Synced Nov 2, 2026, 2:32 PM EST
Completed Phase 3 Interventional

Iressa Expanded Access Program (EAP)

NCT00034879
View directory record Official record
Conditions
Carcinoma, Non-small-cell Lung, Metastases, Neoplasm
Interventions
ZD1839 (Gefitinib)
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2003
U.S. locations
626
States / cities
Alabaster, Alabama • Anniston, Alabama • Birmingham, Alabama + 623 more
Source: ClinicalTrials.gov public record
Updated Jan 4, 2013 · Synced Nov 2, 2026, 2:32 PM EST
Active, not recruiting Phase 2 Interventional Results available

Metformin for the Prevention of Oral Cancer in Patients With Oral Leukoplakia or Erythroplakia

NCT05237960
View directory record Official record
Conditions
Erythroplakia, Oral Leukoplakia
Interventions
Biopsy, Biospecimen Collection, Extended Release Metformin Hydrochloride, Placebo Administration
Procedure · Drug
Lead sponsor
University of Arizona
Other
Eligibility
21 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
8
States / cities
Tucson, Arizona • San Diego, California • Tampa, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Sep 28, 2026 · Synced Nov 2, 2026, 2:32 PM EST
Terminated Phase 2 Interventional Results available

Neoadjuvant Chemohormonal Therapy Followed by Salvage Surgery for High Risk PSA

NCT01531205
View directory record Official record
Conditions
Prostate Cancer
Interventions
Androgen Ablation, Cabazitaxel, Salvage Therapy, Neoadjuvant Treatment - Hormonal Therapy, Neoadjuvant Treatment - Cabazitaxel
Drug
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older · Male only
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Nov 5, 2014 · Synced Nov 2, 2026, 2:32 PM EST
Recruiting Phase 1 Interventional

Dose Escalation and Expansion Study of BH3120 Alone or With Pembrolizuamb in Advanced or Metastatic Solid Tumors

NCT06234397
View directory record Official record
Conditions
Advanced or Metastatic Solid Tumors
Interventions
BH3120, pembrolizumab
Drug
Lead sponsor
Hanmi Pharmaceutical Company Limited
Industry
Eligibility
18 Years and older
Enrollment
216 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
5
States / cities
Tampa, Florida • Grand Rapids, Michigan • Cincinnati, Ohio + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Nov 2, 2026, 2:32 PM EST